FDA Approves ZOLL’s Zenix Monitor/Defibrillator

ZOLL has received U.S. Food and Drug Administration (FDA) approval for Zenix, its most advanced and easy-to-use professional monitor/defibrillator.

Zenix was built from years of feedback from customers and the company said it combines intuitive design with powerful functionality to boost patient care and automate workflows. It boasts a large, durable touchscreen to offer critical information when needed. On-the-fly customization capabilities also let healthcare professionals make real-time adjustments to stay in control during high-pressure situations.

The tech is equipped with ZOLL’s Real BVM Help and Real CPR technology to offer real-time clinical feedback to improve ventilation quality and deliver high-quality CPR. The Zenix/monitor/defibrillator is now available to U.S. customers.

“Whether you are a hospital clinician or an EMS professional, the ZOLL Zenix monitor/defibrillator is designed to work the way you work,” said Elijah White, president of ZOLL Acute Care Technology. “Zenix is our most advanced monitor/defibrillator, and yet it’s incredibly easy to use—virtually all functions of the device are accessible with three screen-touches or less. Along with the X Series and R Series, Zenix extends ZOLL’s leadership in professional monitors/defibrillators with unique features and intuitive design.”

The company specializes in products or defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment.